News from bayer healthcare pharmaceuticals inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 09, 2015, 10:29 ET Bayer Presents New Data on BETASERON® (interferon beta-1b) at ECTRIMS 2015

Bayer HealthCare Pharmaceuticals Inc. announced today that new research studying BETASERON® (interferon beta-1b) will be presented at the 31st...

Sep 25, 2015, 07:00 ET Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved BETACONNECT, the first and only electronic autoinjector in ...

Sep 14, 2015, 02:30 ET Bayer to Showcase Data from Growing Oncology Franchise at ECC2015 in Vienna

Bayer HealthCare Pharmaceuticals Inc. announced today that data from its growing oncology portfolio will be presented at the 2015 European Cancer...

Aug 24, 2015, 08:30 ET Bayer to Bring Prostate Cancer Awareness to Center Court with Coaches vs. Cancer Partnership

Bayer HealthCare today announced a new partnership with Coaches vs. Cancer, an awareness initiative led by the American Cancer Society and the...

Aug 14, 2015, 12:00 ET National Hemophilia Foundation's (NHF) 67th Annual Meeting: Astronaut Dr. Mae Jemison and Bayer Bring Science Education Message to Hemophilia Patients at NHF Event

Bayer HealthCare will host an event for members of the bleeding disorders community, patients and their families during the National Hemophilia...

Jun 17, 2015, 02:30 ET Bayer to Present New Data on Copanlisib in Hematological Malignancies

Bayer HealthCare will present latest data from its investigational compound copanlisib at the 13th International Conference on Malignant Lymphoma...

Jun 01, 2015, 10:16 ET Survey Shows Most Men with Advanced Prostate Cancer Ignore their Symptoms as Disease Progresses[1]

While men living with advanced prostate cancer experience a range of symptoms like severe or unexplained pain, difficulty walking or climbing stairs, ...

May 11, 2015, 11:18 ET Chester, N.J. Woman Wins Bayer's Breathless Moments Contest

Bayer is pleased to announce the winner of Breathless Moments, a photo contest designed to raise awareness about chronic thromboembolic pulmonary...

Feb 23, 2015, 09:00 ET Bayer Healthcare Expands Patient Assistance Program To Include An Additional Intrauterine Device At No Cost To Women Who Qualify

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH...

Feb 23, 2015, 05:01 ET Bayer Presents Latest Oncology Research at ASCO GU 2015

Bayer HealthCare Pharmaceuticals Inc. announced today that new data on Xofigo® (radium Ra 223 dichloride) injection will be presented at the 2015...

Sep 24, 2014, 02:30 ET ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including Stivarga® (regorafenib) tablets, NEXAVAR®...

Sep 16, 2014, 02:30 ET Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with...

Aug 13, 2014, 08:30 ET Over 1,000 Medical Sites in the United States Now Licensed to Administer Xofigo® (radium Ra 223 dichloride) Injection

Bayer HealthCare Inc. today announced that, approximately one year following the national launch, over 1,000 sites in the United States have received ...

Apr 02, 2014, 02:30 ET Bayer Initiates Phase 3 Trial of Xofigo® (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer

Bayer HealthCare Pharmaceuticals Inc. today announced that the company has begun to enroll patients in a trial studying Xofigo® (radium Ra 223...

Mar 03, 2014, 08:00 ET Advocacy Organization Fight Colorectal Cancer and Bayer Kick-Start Colorectal Cancer Awareness Month at National Historic Landmark

To raise awareness about colorectal cancer—the nation's second leading cause of cancer-related deaths—Fight Colorectal Cancer, a leading patient...

Feb 20, 2014, 02:30 ET Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in...

Feb 18, 2014, 02:15 ET Bayer's Long-Acting Recombinant Factor VIII Demonstrated Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III Trial

Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific...

Nov 20, 2013, 11:14 ET Bayer's Third Annual Virtual Walk for Hemophilia Raises Funds, Brings Together the Hemophilia Community

Bayer HealthCare and the National Hemophilia Foundation (NHF) today announced the successful conclusion of the third annual Virtual Walk for...

Sep 20, 2013, 07:40 ET Xofigo® (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use (CHMP) recommended Xofigo® (radium Ra 223...

Jul 17, 2013, 05:01 ET The New England Journal of Medicine Publishes Results from the Phase III ALSYMPCA Study of Xofigo® (radium Ra 223 dichloride) Injection

Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial of its drug Xofigo®...

Jul 08, 2013, 04:28 ET Bayer Initiates Phase III Trial of an Investigational Recombinant Factor VIII Compound in Children with Hemophilia A

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational...

May 15, 2013, 11:40 ET Bayer Receives U.S. FDA Approval for Xofigo® (radium Ra 223 dichloride) Injection as a New Treatment for Castration-Resistant Prostate Cancer with Bone Metastases

Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium Ra 223...

May 15, 2013, 06:01 ET Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets,...

May 15, 2013, 02:30 ET Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular...

May 08, 2013, 08:00 ET Bayer to Present Data on Investigational Pulmonary Hypertension Compound Riociguat at ATS 2013

Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a...